published by john wiley  sons ltd.analysis 1.8. comparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 8 mycological cure rate short-term subgroup analysis.review probiotics for vulvovaginal candidiasis in non-pregnant womencomparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 8 mycological cure rate short-term subgroup analysisstudy or subgroupprobiotics  conventional antifungal drugsconventional antifungaldrugsrisk ratioweightrisk rationnnnm-hfixed95 cim-hfixed95 cisubtotal 95 ci45458.7 1.14  0.97 1.33 total events 42 probiotics  conventional antifungal drugs 37 conventional antifungal drugs heterogeneity not applicabletest for overall effect z  1.59 p  0.11total 95 ci485484100.0 1.06  1.02 1.10 total events 452 probiotics  conventional antifungal drugs 426 conventional antifungal drugs heterogeneity chi2  4.48 df  6 p  0.61 i2 0.0test for overall effect z  2.77 p  0.0057test for subgroup differences chi2  0.86 df  1 p  0.35 i2 0.00.010.1110100favors conventional antifungal drugsfavors probiotics  conventional antifungal drugsprobiotics for vulvovaginal candidiasis in non-pregnant women review56analysis 1.9. comparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 9 mycological non-cure short-termcandida albicans versus non-albicans.review probiotics for vulvovaginal candidiasis in non-pregnant womencomparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 9 mycological non-cure short-termcandida albicans versus non-albicansstudy or subgroupprobiotics  conventional antifungal drugsconventional antifungaldrugsrisk ratioweightrisk ratio1 candida albicansnnnnm-hfixed95 cim-hfixed95 cinouraei 201224244150.3 0.49  0.09 2.52 subtotal 95 ci424150.3 0.49  0.09 2.52 total events 2 probiotics  conventional antifungal drugs 4 conventional antifungal drugs heterogeneity not applicabletest for overall effect z  0.86 p  0.39 2 non-albicansnouraei 2012134449.7 0.42  0.11 1.53 subtotal 95 ci3449.7 0.42  0.11 1.53 total events 1 probiotics  conventional antifungal drugs 4 conventional antifungal drugs heterogeneity not applicabletest for overall effect z  1.32 p  0.19total 95 ci4545100.0 0.45  0.16 1.30 total events 3 probiotics  conventional antifungal drugs 8 conventional antifungal drugs heterogeneity chi2  0.02 df  1 p  0.88 i2 0.0test for overall effect z  1.47 p  0.14test for subgroup differences chi2  0.02 df  1 p  0.88 i2 0.00.010.1110100favors conventional antifungal drugsfavors probiotics  conventional antifungal drugsprobiotics for vulvovaginal candidiasis in non-pregnant women review57analysis 1.10. comparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 10 mycological cure rate long-term1 month after treatment.review probiotics for vulvovaginal candidiasis in non-pregnant womencomparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 10 mycological cure rate long-term1 month after treatmentstudy or subgroupprobiotics  conventional antifungal drugsconventional antifungaldrugsrisk ratioweightrisk rationnnnm-hrandom95cim-hrandom95citotal events 277 probiotics  conventional antifungal drugs 206 conventional antifungal drugs heterogeneity tau2  0.08 chi2  28.30 df  1 p0.00001 i2 96test for overall effect z  1.06 p  0.29 2 oral administration of probioticsmartinez 20091718152128.0 1.32  0.99 1.77 subtotal 95 ci182128.0 1.32  0.99 1.77 total events 17 probiotics  conventional antifungal drugs 15 conventional antifungal drugs heterogeneity not applicabletest for overall effect z  1.87 p  0.062total 95 ci314313100.0 1.26  0.93 1.71 total events 294 probiotics  conventional antifungal drugs 221 conventional antifungal drugs heterogeneity tau2  0.06 chi2  28.28 df  2 p0.00001 i2 93test for overall effect z  1.50 p  0.13test for subgroup differences chi2  0.06 df  1 p  0.80 i2 0.00.010.1110100favors conventional antifungal drugsfavors probiotics  conventional antifungal drugsprobiotics for vulvovaginal candidiasis in non-pregnant women review58analysis 1.11. comparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 11 mycological cure rate long-term1 month after treatment sensitivity analysis.review probiotics for vulvovaginal candidiasis in non-pregnant womencomparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 11 mycological cure rate long-term1 month after treatment sensitivity analysisstudy or subgroupprobiotics  conventional antifungal drugsconventional antifungaldrugsrisk ratioweightrisk rationnnnm-hfixed95 cim-hfixed95 ci martinez 200917181521100.0 1.32  0.99 1.77 total 95 ci1821100.0 1.32  0.99 1.77 total events 17 probiotics  conventional antifungal drugs 15 conventional antifungal drugs heterogeneity not applicabletest for overall effect z  1.87 p  0.062 test for subgroup differences not applicable0.010.1110100favors conventional antifungal drugsfavors probiotics  conventional antifungal drugsanalysis 1.12. comparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 12 mycological cure rate long-term3 months after treatment.review probiotics for vulvovaginal candidiasis in non-pregnant womencomparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 12 mycological cure rate long-term3 months after treatmentstudy or subgroupprobiotics  conventional antifungal drugsconventional antifungaldrugsrisk ratioweightrisk rationnnnm-hfixed95 cim-hfixed95 ci zhang 200575876385100.0 1.16  1.00 1.35 total 95 ci8785100.0 1.16  1.00 1.35 total events 75 probiotics  conventional antifungal drugs 63 conventional antifungal drugs heterogeneity not applicabletest for overall effect z  1.96 p  0.050 test for subgroup differences not applicable0.010.1110100favors conventional antifungal drugsfavors probiotics  conventional antifungal drugsprobiotics for vulvovaginal candidiasis in non-pregnant women review59copyright c 2017 the cochrane collaboration.

probiotics as adjuvants therapy was as- sociated with a significantly improved on short-term clinical cure rate when compared to conventional antifungal drugs alone com- bined rr 1.14 95 ci 1.05 to 1.24 5 trials 695 participants i2  28 analysis 1.1 figure 4.figure 4. forest plot of comparison 2 probiotics  conventional antifungal drugs versus conventional antifungal drugs outcome 1.1 clinical cure rate short-term.a sensitivity analysis excluding the four studies at high risk of bias han 2006 hua 2008 ma 2007 yang 2009 only included nouraei 2012 however the rate of short-term clinical cure was still significantly increased in the probiotics used as adjuvants group compared to the conventional antifungal drugs alone group rr 1.41 95 ci 1.07 to 1.84 1 trial 90 participants analysis 1.2. the grade quality of the evidence for this outcome was low due to the limitations of risk of bias see summary of findings for the main comparison for details.clinical cure rate long-term one month after treatmentonly one trial reported the long-term clinical cure rate at one month after treatment zhang 2005. there was no significant improvement associated with probiotics as adjuvant therapy on long-term clinical cure rate at one month after treatment compared to conventional antifungal drugs alone rr 1.07 95 ci 0.86 to 1.33 1 trial 172 participants analysis 1.4.the quality of the evidence for this outcome was very low due tothe limitations of risk of bias and imprecision see summary of findings for the main comparison for details.clinical cure rate long-term three months after treatmentone trial reported long-term clinical cure rate at three months after treatment zhang 2005. there was no significant improve- ment associated with probiotics as adjuvant therapy on long-term clinical cure rate at three months after treatment compared to con- ventional antifungal drugs alone rr 1.30 95 ci 1.00 to 1.701 trial 172 participants analysis 1.5.the quality of the evidence for this outcome was very low due to the limitations of risk of bias and imprecision see summary of findings for the main comparison for details.mycological cure rate short-term zero to 14 days after treatmentseven trials with 969 participants evaluated short-term mycolog- ical cure rate han 2006 lin 2006 ma 2007 mai 2007 hua2008 yang 2009 nouraei 2012.in the probiotics used as adjuvants to conventional antifungal drugs group mycological cure occurred in 452485 participants.

ofparticipantsstatistical methodeffect sizeclinical cure rate short-term5695risk ratio m-h fixed 95 ci1.14 1.05 1.24clinical cure rate short-term sensitivity analysis190risk ratio m-h fixed 95 ci1.41 1.07 1.84long-term1 month after treatment sensitivity analysis12 mycological cure rate long-term3 months after1172risk ratio m-h fixed 95 ci1.16 1.00 1.35eventsanalysis 1.1. comparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 1 clinical cure rate short-term.review probiotics for vulvovaginal candidiasis in non-pregnant womencomparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 1 clinical cure rate short-termanalysis 1.2. comparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 2 clinical cure rate short-term sensitivity analysis.review probiotics for vulvovaginal candidiasis in non-pregnant womencomparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 2 clinical cure rate short-term sensitivity analysisstudy or subgroupprobiotics  conventional antifungal drugsconventional antifungaldrugsrisk ratioweightrisk rationnnnm-hfixed95 cim-hfixed95 ci nouraei 201238452745100.0 1.41  1.07 1.84 total 95 ci4545100.0 1.41  1.07 1.84 total events 38 probiotics  conventional antifungal drugs 27 conventional antifungal drugs heterogeneity not applicabletest for overall effect z  2.49 p  0.013 test for subgroup differences not applicable0.010.1110100favors conventional antifungal drugsfavors probiotics  conventional antifungal drugsprobiotics for vulvovaginal candidiasis in non-pregnant women review51copyright c 2017 the cochrane collaboration.

published by john wiley  sons ltd.analysis 1.4. comparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 4 clinical cure rate long-term1 month after treatment.review probiotics for vulvovaginal candidiasis in non-pregnant womencomparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 4 clinical cure rate long-term1 month after treatmentstudy or subgroupprobiotics  conventional antifungal drugsconventional antifungaldrugsrisk ratioweightrisk rationnnnm-hfixed95 cim-hfixed95 ci zhang 200559875485100.0 1.07  0.86 1.33 total 95 ci8785100.0 1.07  0.86 1.33 total events 59 probiotics  conventional antifungal drugs 54 conventional antifungal drugs heterogeneity not applicabletest for overall effect z  0.59 p  0.55 test for subgroup differences not applicable0.010.1110100favors conventional antifungal drugsfavors probiotics  conventional antifungal drugsanalysis 1.5. comparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 5 clinical cure rate long-term3 months after treatment.review probiotics for vulvovaginal candidiasis in non-pregnant womencomparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 5 clinical cure rate long-term3 months after treatmentstudy or subgroupprobiotics  conventional antifungal drugsconventional antifungaldrugsrisk ratioweightrisk rationnnnm-hfixed95 cim-hfixed95 ci zhang 200556874285100.0 1.30  1.00 1.70 total 95 ci8785100.0 1.30  1.00 1.70 total events 56 probiotics  conventional antifungal drugs 42 conventional antifungal drugs heterogeneity not applicabletest for overall effect z  1.95 p  0.051 test for subgroup differences not applicable0.010.1110100favors conventional antifungal drugsfavors probiotics  conventional antifungal drugsprobiotics for vulvovaginal candidiasis in non-pregnant women review53copyright c 2017 the cochrane collaboration.

diagnosis of vvc was confirmed by the presence of clinical symptoms and signs and a positive microscopic examination or positive vaginal culture or both.we excluded trials of women with rvvc diabetes mellitus im- munosuppressive disorders taking immunosuppressant medica- tion or trials that recruited women with evidence of coinfection with other vulvovaginal infections.types of interventionsany probiotic single or multiple strains any preparation type dosage regimen or route of administration.used alone versus conventional antifungal drugs.used as adjuvants to conventional antifungal drugs before during or after antifungal treatment versus conventional antifungal drugs alone.conventional antifungal drugs described here refer to the com- mon drugs for vvc treatment such as azole drugs triazoles and imidazoles and nystatin.types of outcome measuresprimary outcomesclinical cure rate disappearance of symptoms and signs and no evidence of fungal infection proved by microscopic examination or vaginal culture split into 'short-term clinical cure rate' zero to 14 days after treatment and 'long-term clinical cure rate' one three and six months after treatment.mycological cure rate no evidence of fungal infectionproved by microscopic examination or vaginal culture split into 'short-term mycological cure rate' zero to 14 days after treatment' and 'long-term mycological cure rate' one three and six months after treatment.relapse rate symptom recurrence confirmed bymicroscopic examination or vaginal culture at one three and six after mycological cure.rate of serious adverse events death internal organ injurysevere skin and mucosal injury.secondary outcomestime to first relapse.rate of non-serious adverse events mild symptoms include vomiting diarrhea abdominal pain abnormal urination pelvic cramps paresthesia rhinorrhea headache dizziness fever chills vaginal burning stinging itching and irritation.need for any additional treatment at the end of therapy.patient satisfaction with treatment.cost effectiveness.search methods for identification of studieswe attempted to identify as many relevant rcts as possible of probiotics for vvc regardless of language publication date or publication status published unpublished in press and in progress.

the results did not seem to show a significant improvement between the two groups in long-term clinical cure rate at one month after treatment rr 1.07 95 ci 0.86 to 1.33 and at three months after treatment rr 1.30 95 ci 1.00 to 1.70.compared with conventional antifungal drugs alone theaddition of probiotics could enhance their effect in improving short-term mycological cure rate rr 1.06 95 ci 1.02 to 1.10 but the addition of probiotics did not seem to be different to conventional antifungal drugs used alone in improving the long-term mycological cure rate at one month after treatment rr 1.26 95 ci 0.93 to 1.71 and at three months aftertreatment rr 1.16 95 ci 1.00 to 1.35.compared with conventional antifungal drugs alone the addition of probiotics may reduce the first relapse rate at one month after treatment rr 0.34 95 ci 0.17 to 0.68. however this result should be interpreted with caution because of the limitations related to the low quality of primary studies.there appears to be no difference between the addition ofprobiotics to conventional antifungal drugs and conventional antifungal drugs alone in the rate of serious adverse events rr 0.80 95 ci 0.22 to 2.94 the reported adverse events included severe vaginal burning stinging or rash after the first use of miconazole nitrate vaginal suppository.there was no difference between the addition of probioticsto conventional antifungal drugs and conventional antifungal drugs alone in the rate of non-serious adverse events rr 0.90 95 ci 0.48 to 1.70. the reported adverse events included mild vaginal dryness burning stinging headache loose stool and nausea.there was no available evidence for evaluating the time tofirst relapse need for any additional treatment at the end of therapy patient satisfaction with treatment and cost effectiveness.however all the results found in this review should be interpreted with caution because of the limitations related to the low and very low quality of primary studies.overall completeness and applicability of evidencealthough we employed several methods to try to identify all rcts and included both published and unpublished data in this review this systematic review included trials at high risk of bias and con- sequently with very low to low confidence on the estimate of ef- fect see summary of findings for the main comparison.

published by john wiley  sons ltd.analysis 1.6. comparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 6 mycological cure rate short-term.review probiotics for vulvovaginal candidiasis in non-pregnant womencomparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 6 mycological cure rate short-termanalysis 1.7. comparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 7 mycological cure rate short-term sensitivity analysis.review probiotics for vulvovaginal candidiasis in non-pregnant womencomparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 7 mycological cure rate short-term sensitivity analysisstudy or subgroupprobiotics  conventional antifungal drugsconventional antifungaldrugsrisk ratioweightrisk rationnnnm-hfixed95 cim-hfixed95 ci nouraei 201242453745100.0 1.14  0.97 1.33 total 95 ci4545100.0 1.14  0.97 1.33 total events 42 probiotics  conventional antifungal drugs 37 conventional antifungal drugs heterogeneity not applicabletest for overall effect z  1.59 p  0.11 test for subgroup differences not applicable0.010.1110100favors conventional antifungal drugsfavors probiotics  conventional antifungal drugsprobiotics for vulvovaginal candidiasis in non-pregnant women review55copyright c 2017 the cochrane collaboration.

probiotics as adjuvants therapy was associated with no significant improvement on long-term my- cological cure rate at one month after treatment when compared to conventional antifungal drugs alone rr 1.26 95 ci 0.93 to 1.71 3 trials 627 participants i2  93 analysis 1.10 figure6.figure 6. forest plot of comparison 2 probiotics  conventional antifungal drugs versus conventional antifungal drugs outcome 1.10 mycological cure rate long-term1 month after treatment.a sensitivity analysis excluding two trials at high risk of bias zhang 2005 kovachev 2015 only included martinez 2009 however the rate of long-term mycological cure rate at one month after treatment was still not significantly difference between probiotics used as adjuvants and conventional antifungal drugs alone rr 1.32 95 ci 0.99 to 1.77 1 trial 90 participants analysis 1.11. this result must be treated and interpreted carefully because of the small sample.the quality of the evidence for this outcome was very low due to the limitations of risk of bias imprecision and inconsistency see summary of findings for the main comparison for details.mycological cure rate long-term three months after treatmentonly one trial with 172 participants reported long-term myco- logical cure rate at three months after treatment zhang 2005. there was no statistically significant difference between probiotics used as adjuvants and conventional antifungal drugs alone in the rate of long-term mycological cure at three months after treatmentrr 1.16 95 ci 1.00 to 1.35 1 trial 172 participants analysis1.12.the quality of the evidence for this outcome was very low due to the limitations of risk of bias and imprecision see summary of findings for the main comparison for details.relapse ratethree trials with 388 participants evaluated first relapse after treat- ment han 2006 hua 2008 yang 2009. in the probiotics used as adjuvants to conventional antifungal drugs group relapse oc- curred in 10202 participants.

published by john wiley  sons ltd.analysis 1.13. comparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 13 relapse rate.review probiotics for vulvovaginal candidiasis in non-pregnant womencomparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugsanalysis 1.14. comparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 14 rate of serious adverse events.review probiotics for vulvovaginal candidiasis in non-pregnant womencomparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 14 rate of serious adverse eventstotal events 4 probiotics  conventional antifungal drugs 5 conventional antifungal drugs heterogeneity chi2  0.09 df  1 p  0.76 i2 0.0test for overall effect z  0.34 p  0.74 test for subgroup differences not applicable0.010.1110100favors conventional antifungal drugsfavors probiotics  conventional antifungal drugsprobiotics for vulvovaginal candidiasis in non-pregnant women review61copyright c 2017 the cochrane collaboration.

lactis dm8909 each capsule contained 0.25 x 106 colony forming units qd from day 7 to day 16.miconazole alone group 1 vaginal suppository of miconazole nitrate 400 mg qd from day 1 to day 6outcomesfollow-up at 5-7 days and 33-37 days after completion of treatment clinical and labo- ratory symptoms were re-evaluatedoutcomesclinical cure rate 5-7 days after completion of treatmentmycological cure rate 5-7 days after completion of treatmentrelapse rate 33-37 days after completion of treatment visited participants who were mycological cured 5-7 days after completion of treatmentrate of adverse events.notesstudy obtained written consent from all participants and had ethical clearance from review committee of hospitalno funding source or declaration of interest reported.risk of biasbiasauthors' judgementsupport for judgementrandom sequence generation selection biaslow riskwe contacted the original author and found that they used a draw method all participants were numbered on individual pieces of paper then took the paper rele- vant to participant out of a container with- out being able to see what was written on itallocation concealment selection bias low riskwe contacted the original author and found that they used codified opaque sealed envelopesblinding of participants and personnel performance biasall outcomeshigh risksingle blinding for all investigators.we consider the judgment of symptoms and signs outcomes by participants may have been influencedblinding of outcome assessment detection biasall outcomeshigh riskblinding of outcome assessors.but we consider outcome assessors may have been influenced by participants be- cause there was no blinding to participantsincomplete outcome data attrition bias all outcomeshigh riskreported withdrawals rate of 2.1 less than 20 during the treatment but thehua 2008 continuedkovachev 2015methodssingle-center randomized open-label study.setting outpatient group practice for specialized care in obstetrics and gynecology gynart sofia bulgariastudy period 2008-2013.participantsinclusion criteria aged 17-50 years with clinically or microbiologically identified pre- dominantly candida albicans vaginal infections.exclusion criteria pregnant infection with neisseria gonorrhoeae herpes simplex virus human papillomavirus chlamydia trachomatis or hiv using corticosteroids antibiotics azoles or probiotics within last month using vaginal agents within last month immuno- compromised diseases autoimmune diseases endocrine diseases diabetes diseases or malignanciesnumber enrolled 436 women enrolled and randomized.numbers per group azole  vaginal probiotic 217 azole alone 219lost to follow-up after treatment azole  vaginal probiotic 8 azole alone 12 original author did not use intention-to-treat analyses.interventionsazole  vaginal probiotic group oral fluconazole 150 mg  1 vaginal globule of fenti- conazole 600 mg on same day however 10 applications of vaginal probiotics lacto- bacillus acidophilus lactobacillus rhamnosus streptococcus thermophilus and lactobacillus delbrueckii subsp.

published by john wiley  sons ltd.analysis 1.3. comparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 3 clinical cure rate short-term subgroup analysis.review probiotics for vulvovaginal candidiasis in non-pregnant womencomparison 1 probiotics plus conventional antifungal drugs versus conventional antifungal drugs outcome 3 clinical cure rate short-term subgroup analysisstudy or subgroupprobiotics  conventional antifungal drugsconventional antifungaldrugsrisk ratioweightrisk rationnnnm-hfixed95 cim-hfixed95 cisubtotal 95 ci454510.8 1.41  1.07 1.84 total events 38 probiotics  conventional antifungal drugs 27 conventional antifungal drugs heterogeneity not applicabletest for overall effect z  2.49 p  0.013total 95 ci347348100.0 1.14  1.05 1.24 total events 286 probiotics  conventional antifungal drugs 251 conventional antifungal drugs heterogeneity chi2  5.59 df  4 p  0.23 i2 28test for overall effect z  3.26 p  0.0011test for subgroup differences chi2  2.70 df  1 p  0.10 i2 630.010.1110100favors conventional antifungal drugsfavors probiotics  conventional antifungal drugsprobiotics for vulvovaginal candidiasis in non-pregnant women review52copyright c 2017 the cochrane collaboration.

one trial compared oral fluconazole and vaginal fenticonazole antifungal medicines with oral fluconazole plus vaginal fenticonazole plus probiotic.key resultscompared with conventional antifungal drugs used alone probiotics as adjuvant therapy could enhance their effect in improving the rate of short-term within five to 10 days clinical cure short-term mycological cure no abnormal laboratory results and relapse atone month recurrence of problems but does not seem to influence the rate of long-term within one to three months clinical cure long-term mycological cure serious and non-serious side events.however because of the low quality of evidence available there is insufficient evidence for the use of probiotics as adjuvants to conventional antifungal medicines or used alone for the treatment of vvc in non-pregnant women.quality of the evidencethe quality of the evidence was low or very low in this review so we have very little confidence in the results.s u m m a r y o f f i n d i n g s f o r t h e m a i n c o m p a r i s o n probiotics used as adjuvants to conventional antifungal drugs compared with conventional antifungal drugs for the treatment of vulvovaginal candidiasis in non- pregnant womenpatient or population non-pregnant wom en with vulvovaginal candidiasissettings outpatient clinics in brazil bulgaria iran and chinaintervention probiotics used as adjuvants to conventional antif ungal drugscomparison conventional antif ungal drugsoutcomesillustrative comparative risks 95 cirelative effect 95 ciassumed riskcorresponding riskno of participants studiesquality of the evi- dencegradecommentsconventional anti- fungal drugsprobiotics used as adjuvants to con- ventional antifungal drugsclinical cure rate short- termf ollow-up 5-10 daysm edium risk populationrr 1.14 1.05 to 1.24721 per 1000822 per 1000757 to 8946955oo-low1635 per 1000679 per 1000546 to 8453monthsafter treatmentf ollow-up 3 m onthsm edium risk populationrr 1.30 1.00 to 1.70494 per 1000642 per 1000494 to 8401721ooo-very low12m ycological cure rate short- termf ollow-up 5-10 daysm edium risk populationrr 1.06 1.02 to 1.10880 per 1000933 per 1000898 to 9689697oolow1see 3 in f ootnotes.m ycologicalcure rate long- term1 month after treat- mentf ollow-up28-30 daysm edium risk populationrr 1.26 0.93 to 1.71706 per 1000890 per 1000657 to 10006273ooovery low124see 5 in f ootnotes.3monthsafter treatmentf ollow-up 3 m onthsm edium risk populationrr 1.16 1.00 to 1.35741 per 1000860 per 1000741 to 10001721ooo-very low12relapse ratef ollow-up 30-37 days af ter treatm entm edium risk populationrr 0.34 0.17 to 0.68145 per 100049 per 100025 to 993883ooo-very low16rate of serious adverse eventsf ollow-up 5-90 days af ter treatm entm edium risk populationrr 0.80 0.22 to 2.9423 per 100018 per 10005 to 684402oo-low12 the basis f or the assumed risk e.g.

probiotics as adjuvants therapy was associated with a significantly improved short-term mycolog- ical cure rate compared conventional antifungal drugs alone rr 1.06 95 ci 1.02 to 1.10 7 trials 969 participants i2  0analysis 1.6 figure 5.figure 5. forest plot of comparison 2 probiotics  conventional antifungal drugs versus conventional antifungal drugs outcome 1.6 mycological cure rate short-term.a sensitivity analysis excluding the six trials at high risk of bias han 2006 lin 2006 ma 2007 mai 2007 hua 2008 yang2009 only included nouraei 2012 it found the rate of short-term mycological cure was no longer significantly difference between the groups rr 1.14 95 ci 0.97 to 1.33 1 trial 90 participants analysis 1.7. the result of this sensitivity analysis must be treated and interpreted carefully because of the small sample in nouraei 2012.the quality of the evidence for this outcome was low due to the limitations of risk of bias see summary of findings for the main comparison for details.mycological cure rate long-term one month after treatmentthree trials with 627 participants evaluated long-term mycological cure rate at one month after treatment zhang 2005 martinez 2009 kovachev 2015.in the probiotics used as adjuvants to conventional antifungal drugs group mycological cure occurred in 294314 participants.

subgroups did not appear to be different p  0.10 analysis 1.3 figure 9. the effect of the intervention for this outcome did not change according to these intervention characteristics.figure 9. forest plot of comparison 2 probiotics  conventional antifungal drugs versus conventional antifungal drugs outcome 1.3 clinical cure rate short-term subgroup analysis.in the analyses for mycological cure rate short-term zero to 14 days after treatment we explored whether differences in species of probiotics and route of administration intravaginal administra- tion of single species of probiotic or oral administration of multi- ple species of probiotics subgroups did not appear to be different p  0.35 analysis 1.8 figure 10. the effect of the intervention for this outcome did not change according to these intervention characteristics.figure 10. forest plot of comparison 2 probiotics  conventional antifungal drugs versus conventional antifungal drugs outcome 1.8 mycological cure rate short-term subgroup analysis.in addition we explored the differences between different candidal strains candida albicans versus non-albicans and found that the subgroup estimates for the different candidal strains did not differ significantly in the oral administration of probiotics p  0.88 analysis 1.9.in the analyses mycological cure rate long-term one month after treatment we explored the differences between routes of admin- istration intravaginal or oral administration subgroups did not appear to be different p  0.80 analysis 1.10. subgroup analysisdid not appear to explain the variability in the overall summary effect measures for the outcome long-term mycological cure rate so these findings should be interpreted with caution.we did not perform the subgroup analysis age group of partici- pants because none of the included trials provided information.d i s c u s s i o nsummary of main resultsten rcts including 1656 participants fulfilled the inclusion crite- ria and were included.

occasionally vvc can cause external dysuria difficult or painful urination by the burning that occurs when urine hits the inflamed vulvar tissues eckert 1998. if there is an odor it is gen- erally insignificant and inoffensive sobel 2007. clinical symp- toms may recur or exacerbate in the week before menstruation schaaf 1990 anderson 2004 sobel 2007. on vulvar examina- tion women may exhibit erythema redness of the skin caused by dilation and congestion of the capillaries often a sign of inflam- mation or infection swelling fissures or excoriations of the labia and vulva and vaginal signs of erythema or an adherent curd-like vaginal discharge may be found sobel 1998 nyirjesy 2003 sobel 2007 nyirjesy 2008.most women with symptoms of vvc can be easily diagnosed whensaline and 10 potassium hydroxide microscopyexamination or gram stain 63.2 to 65 sensitivity 97.2 to 100 specificity omar 2001 ilkit 2011 of vaginal discharge demonstrates candida species hyphae or pseudohyphae ora vaginal culture test yields a candida species sobel 1998sobel 2007 nyirjesy 2008 cdc 2015.because candida vaginitis is associated with a normal vaginal phless than 4.5 ph testing is not useful for diagnosis but the find- ing of a normal ph helps to exclude bacterial vaginosis trichomo- niasis atrophic vaginitis or some type of mixed infection nyirjesy 2008 cdc 2015.the 10 potassium hydroxide microscopy examination 50 to 85 sensitivity should be taken for all women with symptoms or signs of vvc and women with a positive result should receive treatment ilkit 2011 mylonas 2011. the gold standard for diag- nosis is still the growth of the infecting organism in fungal culture on sabouraud dextrose agar ilkit 2011. up to 50 of women with culture-positive symptomatic vulvovaginal candidiasis will have negative microscopy sobel 2007 so although routine cul- tures are not necessary if microscopy is positive vaginal culture should be performed for women with a negative microscopy result and a normal ph and who are symptomatic sobel 2007 cdc 2015. vaginal culture is useful to identify the species of can- dida bieber 2006. for women with complicated vvc vaginal culture can guide the choice of therapy regimen since non-albi- cans species tend to be resistant to the azole drugs bieber 2006 nyirjesy 2008. table 1 lists species of candida isolated from the lower genital tract in women with vvc.

